Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Expert Opinion on Drug Safety
|
August 9, 2003
Cardiotoxic effects of anthracycline-taxane combinations
Antonella Perotti, Sara Cresta, Giacomo Grasselli, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
April 22, 2003
Anthracyclines
Luca Gianni, Giacomo Grasselli, Sara Cresta, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
September 2, 2004
Anthracyclines
Luca Gianni, Giacomo Grasselli, Sara Cresta, et al.
Critical Reviews in Oncology/Hematology
|
November 20, 2021
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Margherita Ambrosini, Giovanni Fucà, Matteo Duca, et al.
Breast (Edinburgh, Scotland)
|
September 7, 2018
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Anna Tessari, Lorenzo Pilla, Damian Silvia, et al.
The Breast Journal
|
February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
Gabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Investigational New Drugs
|
March 8, 2013
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, et al.
Targeted Oncology
|
December 28, 2020
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, et al.
Breast Cancer Research : BCR
|
September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
ESMO Open
|
February 22, 2018
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Expert Opinion on Drug Safety
|
August 9, 2003
Cardiotoxic effects of anthracycline-taxane combinations
Antonella Perotti, Sara Cresta, Giacomo Grasselli, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
April 22, 2003
Anthracyclines
Luca Gianni, Giacomo Grasselli, Sara Cresta, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
September 2, 2004
Anthracyclines
Luca Gianni, Giacomo Grasselli, Sara Cresta, et al.
Critical Reviews in Oncology/Hematology
|
November 20, 2021
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Margherita Ambrosini, Giovanni Fucà, Matteo Duca, et al.
Breast (Edinburgh, Scotland)
|
September 7, 2018
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Anna Tessari, Lorenzo Pilla, Damian Silvia, et al.
The Breast Journal
|
February 28, 2019
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
Gabriella Mariani, Giulia Galli, Stefano Cavalieri, et al.
Investigational New Drugs
|
March 8, 2013
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, et al.
Targeted Oncology
|
December 28, 2020
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, et al.
Breast Cancer Research : BCR
|
September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
ESMO Open
|
February 22, 2018
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, et al.
Page
of 3